Intersect ENT Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
18,369.00
18,362.00
26,634.00
25,222.00
16,363.00
22,922
Depreciation, Depletion & Amortization
505.00
583.00
826.00
1,166.00
1,464.00
1,884
Other Funds
30,228.00
-
-
-
-
12,344
Funds from Operations
17,010.00
15,767.00
20,242.00
16,441.00
5,060.00
8,694
Changes in Working Capital
2,091.00
2,187.00
155.00
3,618.00
2,981.00
5,146
Net Operating Cash Flow
19,101.00
17,954.00
20,087.00
20,059.00
8,041.00
13,840
Capital Expenditures
467.00
367.00
1,524.00
2,069.00
2,281.00
Purchase/Sale of Investments
-
35,152.00
55,145.00
4,788.00
11,529.00
Net Investing Cash Flow
467.00
35,519.00
56,669.00
6,857.00
9,248.00
Issuance/Reduction of Debt, Net
548.00
1,452.00
-
-
-
Net Financing Cash Flow
29,802.00
54,582.00
98,162.00
1,966.00
8,771.00
Net Change in Cash
10,234.00
1,109.00
21,406.00
24,950.00
9,978.00
Free Cash Flow
19,568.00
18,321.00
21,611.00
22,128.00
10,322.00
Change in Capital Stock
122.00
56,034.00
98,162.00
1,966.00
8,771.00

About Intersect ENT

View Profile
Address
1555 Adams Drive
Menlo Park California 94025
United States
Employees -
Website http://www.intersectent.com
Updated 07/08/2019
Intersect ENT, Inc. is acommercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.